Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07933887
Overview
This study will evaluate \[68Ga\]Ga-SCP, an investigational radioactive imaging agent, for positron emission tomography/computed tomography (PET/CT) in patients with solid tumors that test positive for fibroblast activation protein (FAP). The main aims are to assess how well \[68Ga\]Ga-SCP PET/CT identifies tumor lesions, evaluate its safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore its potential value for early diagnosis.
Sponsor
The First Affiliated Hospital of Soochow University
Phase
Early Phase 1
ClinicalTrials.gov
NCT07933887Drug / Compound
Eligibility
Inclusion criteria not yet provided.
Help us improve your experience